For example, in colorectal cancer (CRC), the KRAS mutations in Exon 2 (Codons 12 and 13) represent a paradigm that has been established as a negative predictive marker for treatment with epidermal growth factor receptor (EGFR) inhibitors such as cetuximab and panitumumab.1 The discovery of further biomarkers will be accelerated by the recent advances in cancer genomics. This evidence concerns the gene EGFR and colorectal carcinoma.